Immunosuppressants - Thailand

Thailand

Thailand is expected to witness a significant growth in revenue within the Immunosuppressants market.
By the year 2024, it is projected that the revenue will reach an impressive €58.93m.
This positive trend is expected to continue, with an annual growth rate (CAGR 2024-2029) of 15.68%.
As a result, the market volume is estimated to reach €122.10m by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue within the global Immunosuppressants market.
Specifically, it is projected that United States will generate a staggering €32,900.00m in revenue by the year 2024.
Thailand's growing demand for immunosuppressants is driven by the increasing prevalence of autoimmune diseases in the country.

Key regions: Australia, Germany, United Kingdom, United States, France

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The demand for immunosuppressants in Thailand has been increasing steadily over the past few years.

Customer preferences: Patients in Thailand are increasingly opting for immunosuppressants due to the rising prevalence of autoimmune diseases and organ transplant surgeries. The aging population is also contributing to the growing demand for these drugs as older individuals are more susceptible to chronic illnesses.

Trends in the market: The immunosuppressants market in Thailand is expected to continue growing due to the increasing prevalence of chronic diseases and organ transplant surgeries. The market is also being driven by the availability of new and innovative drugs with better efficacy and fewer side effects. Additionally, the government's efforts to improve healthcare infrastructure and increase access to medical facilities are contributing to the growth of the market.

Local special circumstances: Thailand has a well-established healthcare system with a large number of hospitals and clinics. However, the country's healthcare system is still facing challenges such as uneven distribution of healthcare resources and a shortage of healthcare professionals in some areas. These challenges may hinder the growth of the immunosuppressants market in certain regions.

Underlying macroeconomic factors: Thailand's economy has been growing steadily over the past few years, which has led to an increase in healthcare spending. The government has also launched several initiatives to improve healthcare infrastructure and increase access to medical facilities. These factors are expected to contribute to the growth of the immunosuppressants market in Thailand. However, the country is also facing challenges such as an aging population and rising healthcare costs, which may impact the growth of the market in the long run.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.